Scancell Share Discussion Threads

[torquayfan] 22/1/2019 00:07

Yes thanks Berm - a meet with 'meat'! And ON NOW until 24th . . .

CRUK is the 'Co-organiser' and Genentech and Pfizer are also among the 4 main sponsors. A number of Speakers from Genentech and what looks like an intense program of updates from a wide range of speakers on all aspects of cancer vaccines.

Cancer vaccines are back in the limelight - this time no turning back !

Long days and hard work until this on the 24th :-
20:00—23:00 Entertainment

I'm suggesting a CSO and CEO could conclude this sector with a duet rendition of, ''You're the one that I want'' . . (being Moditope of course) - with added oooh ooohs from a certain greatly revered Non Exec. Good idea ?

[torquayfan] 21/1/2019 20:27

Hi ONW,

IMO and with respect your 18948 - ''The conclusion . . . from today's RNS is quite simply that the science is insufficient on its own (and always has been) to commercialise the platforms''. Well obviously. Are you suggesting that Scancell or anyone else have been thinking that excellent science would somehow spontaneously combust into commercial deals ?

Then, ''at last the fact is recognised by the Company''. You see the RNS as recognition by Scancell of a previous failing somehow ? That's odd. These appointments are not primarily commercial but scientific / administrative scientific.

18950. I too hope for, ''more effective commercialisation than has been the case so far''. And I'm impatient for an upturn like you - but summoning patience for a further wait. Meantime, the water in my bucket is half full not half empty.

However, your 18948/50 posts were much enjoyed by the Gallery.

End of for me and ATB

[gooosed] 21/1/2019 20:12

Good find Bs . . . . . thanks for posting.

[drdobson1] 21/1/2019 20:09

Barmooda Shorties
Good to see the real Science experts are on here and Not the Exitable puppies on the MFFF.
Two more PhDs on SCLzp payroll for baBABA to steal their research,He has firm and is CINman.
Total plank and dog dirt.

[bermudashorts] 21/1/2019 20:03

A Cancer Vaccines Keystone Symposia is running in Vancouver from 20th to 24th Jan. The event has been organised in collaboration with CRUK and presenters include Ira Mellman (Genentech), Ugur Sahin (BioNtech) and Cornelis Melief (ISA) - all members of Project Blueprint. Also presenting are Karolinska. Not suggesting for one second that it has any connection with CRUK Grand Challenge but it would be a good time to announce that an award has been made to the one and only cancer vaccine team:)

[the real lozan] 21/1/2019 14:21

Just for Tarquin -

[the real lozan] 21/1/2019 13:27

Having a"tiger by the tail" -
The WISER, more ASTUTE amongst *US ALL* might observe, not rule out, that in =
Having a"tiger by the tail" - There is ALWAYS a RISK, that the 'tiger' might turn around and BITE you.
Only a FOOL would presume, or be 'persuaded' - it won't or worse still = It can't

[tosh123] 21/1/2019 12:55

Very well put ONW.
Someone keeps banging on about mice not dying, but thats exactly what they are "mice".
If the purpose of the SCLP science was to ensure that mice cant die from the big C, then it has done its job, but it isn't, its job is to prove that it can cure humans, and as hundreds of previous trials will tell anyone, what cures mice, doesn't necessarily cure humans.
The evidence is there for all to see that the " industry " is still not convinced, it needs further validation on all fronts, so to just dismiss any form of risk based on lab results in rodents, is utter nonsense.
Lets hope that the two new employees have been employed on the back of a specific " near term " event, and that their respective compensations have been accounted for by means other than the current budget.
Contrary to what some idiots will tell you ( and in fact have been wrongly telling people for over 7 years ), there is still a long way to go before any form of commercial activity can start.
In the meantime, its just about sitting tight or trading until you can achieve a free carry.

[oldnotwise] 21/1/2019 12:23

TF
Surely, if we had a tiger by the tail it still needs more effective commercialisation than has been the case so far. I say this because there's been almost seven years of opportunity to commercialise both platforms, but so far....
Hence my original observation that it still may not be the big plus we hope for. even JC (the eternal optimist) has stated that data is the key, and we have some time to wait for more of that. Admittedly we're seven years further along the path, but the beginning of the conclusion of the conversion of science theory to science fact (post Trials) remains to be shown to the market. When that happens (JC's Data comment), Hopefully we'll be really flying, but however one looks at the big picture, the theory shown to date - however astonishingly compelling- has (thus far) failed to convert the IP to monetary value for shareholders.
Successful trials (or perhaps interim data releases) seem logically to be the key for the major share price lifts. then the Commercialisation is probable rather than possible.
So I'll continue to wait patiently....
AIMO
ATB

[torquayfan] 21/1/2019 10:34

ONW in your first sentence you crank a negative angle out of this interesting RNS. Cheer up ! Let's hope this week we win a GC award and maybe then there'll be more to come.

Rather than 'science is insufficient on its own' I'd say science wise - we may have a tiger by the tail. We'll see. ATB

[oldnotwise] 21/1/2019 09:08

The conclusion I draw from today's RNS is quite simply that the science is insufficient on its own (and always has been) to commercialise the platforms, and at last the fact is recognised by the Company.
I see the move as positive, but not in quite the immediate way for the share price that I'm sure many will. I'm more than happy to be proved wrong with regard to the share price (I'm never going to be upset with a few plus days), but I think patience will be required.... Data's the new driver IMO.
AIMO
ATB

[plasybryn] 20/1/2019 22:19

Courtesy Crumbs on LSEToday 21:12Well now to quote scancell :)... I'll capitalise the bit to go wow at:'post-translational changes arethe result of the stresses to which cancer cells areoften subjected. A case in point is stress-inducedautophagy leading to the post-translational conversion of arginine to citrulline by peptidylarginine deiminase (PAD) enzymes. These modifiedepitopes are presented on MHC-II and stimulateCD4 T-cell responses.20 To this end, we havedemonstrated that stress-induced citrullinatedpeptide epitopes induce potent, cytotoxic CD4T-cell-mediated, antitumour responses that couldconstitute a completely new class of cancertreatment.Nutrient and oxygen deprivation, endoplasmic reticulum (ER) stress, as well as accumulateddeoxyribonucleic acid (DNA) damage by rapidlydividing cancer cells creates a 'stressed' environment. The ability of established tumours to growand survive depends largely on autophagic flux.However, the majority of tumours do not expressMHC-II, as the immunosuppressive tumourenvironment inhibits inflammation. Vaccinatingwith citrullinated peptides induces pro-inflammatory, CD4 Th1 cells that are initially reactivatedwithin the tumour environment by APCs, constitutively expressing MHC-II and autophagy.These reactivated CD4 T cells release IFN?,which upregulates class MHC-II on the tumours,allowing direct recognition by the cytotoxic CD4T cells. We have shown that citrullinated peptidesstimulate CD4 T cells, which do not require CD8responses for antitumour immunity,21,22 and leavea memory response to prevent recurrence.Although our first vaccine targets are vimentinand enolase which are expressed by many cancers, other commonly expressed cytoskeletal, glycolytic, regulatory and chaperone proteins arealso citrullinated under conditions of cellularstress.23–25 In theory, combinations of a select fewcitrullinated peptides could be used to target ALLMAJOR SOLID CANCERS resulting in a step change inthe approach to treating tumours. In addition tocitrullination, other stress-induced post-translational modifications (siPTM) have been observedwithin MHC-bound peptides.26,27 Our overarching hypothesis is that these vaccines based uponsiPTM of proteins will elicit new or boost preexisting immunity that will eliminate tumourswith a low T-cell infiltrate.'

[drdobson1] 20/1/2019 17:52

Just looked at Failed Professor Plum twitter feed.

He says in replying to Chukka Umuna one of the nices and brainiest men in politics and this is what the Village Idiott says

“mate you are way too thick to engage in debate ..”.

baBANA is too thick to see the irony.

Hahahahahahahahaha

[the real lozan] 20/1/2019 16:06

I see the sales of Stella Artois are holding up.

[thelogman] 20/1/2019 15:19

Boring comes to mind with daily drivel, money comes to mind with Ffwd.

[torquayfan] 19/1/2019 10:13

Just for anyone who doesn't get around the BB's, elsewhere a Poster received this from CRUK :-

''Thank you for your interest in Grand Challenge.
We are excited to be announcing the recipients of the Grand Challenge award on the 23rd of January at 00:01 GMT via a press release and our website.''

So that's 'Tuesday night' for most - 1 minute after midnight (then being Wednesday, just) and 7 am for me in Th. on Wednesday.

Nice weekend all . .

[drdobson1] 18/1/2019 20:23

Yes der Leader with the large property portfolio CONsusting of CONopoly money and LEGo bricks.
It is Bzo risk as he us a Multi millionaire investor and is Top Of DENSA you know the opposite of MENSA so hevus TOP Thicko
He has Lost millions here anfod huge EGO is liar and CINvuct

[the real lozan] 18/1/2019 18:00

der leader -
The more one reads of HIS posts, the greater becomes the desire to invest ...
.
.
.
Somewhere ELSE

[drdobson1] 18/1/2019 17:08

How dare baNANA argue with Ricky River about buying shares when he us SO unbslNced
his world is falling so part.
No money due to spending so much onnSCLP.
NomBrexit as Jezza plays a blinder and Jacob Mogger Rees gets a right pasting
No Grande challenge and he will be pushed over edge.
No family to support and already unbalanced as a frog with nine toad toes

[torquayfan] 18/1/2019 14:44

Thanks Mr Trump - nil desperandum

[bermudashorts] 18/1/2019 10:59

TF,

Well we don't know whether the O/S requirements have even been submitted to the FDA yet and if they have whether or not the FDA are processing them. You would hope that they will continue to process and complete existing applications. So there may not be any additional delay at all.

On top of the IND there's a huge amount of other work needed to prepare for a clinical trial. ie. Selecting, negotiating, agreeing contracts & briefing CRO, study investigators and centres, ethics committee/IRB approval etc. etc. Scancell have stated that as soon as the approval is received the trial will be ready to start. That suggests they've already invested a significant amount of time, effort and resource into the US trial so it's hard to see a change now but wdik?